|
1）Yoshiyama Y, Higuchi M, Zhang B, et al. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron. 2007; 53: 337-51
|
|
|
|
2）Lang S. The role of peripheral benzodiazepine receptors (PBRs) in CNS pathophysiology. Curr Med Chem. 2002; 9: 1411-5
|
|
|
|
|
|
3）Corcia P, Tauber C, Vercoullie J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012; 7: e52941
|
|
|
|
|
|
4）Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999; 169: 13-21
|
|
|
|
|
|
5）Turner MR, Cagnin A, Turkheimer FE, et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis. 2004; 15: 601-9
|
|
|
|
|
|
6）Ellis CM, Simmons A, Jones DK, et al. Diffusion tensor MRI assesses corticospinal tract damage in ALS. Neurology. 1999; 53: 1051-8
|
|
|
|
|
|
7）Miyoshi M, Shinotoh H, Wszolek ZK, et al. In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: a PET and MRI study. Parkinsonism Relat Disord. 2010; 16: 404-8
|
|
|
|
|
|
8）Morgan JT, Chana G, Pardo CA, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry. 2010; 68: 368-76
|
|
|
|
|
|
9）Suzuki K, Sugihara G, Ouchi Y, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry. 2013; 70: 49-58
|
|
|
|
|
|
10）Varrone A, Mattsson P, Forsberg A, et al. In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F]FEDAA1106 and PET does not show increased binding in Alzheimerʼs disease patients. Eur J Nucl Med Mol Imaging. 2013; 40: 921-31
|
|
|
|
|
|
11）Yasuno F, Ota M, Kosaka J, et al. Increased binding of peripheral benzodiazepine receptor in Alz-heimerʼs disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry. 2008; 64: 835-41
|
|
|
|
|
|
12）Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010; 67: 446-57
|
|
|
|
|
|
13）Steiner J, Bielau H, Brisch R, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res. 2008; 42: 151-7
|
|
|
|
|
|
14）Hannestad J, Dellagioia N, Gallezot JD, et al. The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: A [11C]PBR28 PET study. Brain Behav Immun. 2013; 33: 181-8
|
|
|
|
|
|
15）Politis M, Giannetti P, Su P, et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology. 2012; 79: 523-30
|
|
|
|
|
|
16）Takano A, Piehl F, Hillert J, et al. In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106. EJNMMI Res. 2013; 3: 30
|
|
|
|
|
|
17）Kumar A, Muzik O, Shandal V, et al. Evaluation of age-related changes in translocator protein (TSPO) in human brain using (11)C-[R]-PK11195 PET. J Neuroinflammation. 2012; 9: 232
|
|
|
|
|
|
18）Hines CS, Fujita M, Zoghbi SS, et al. Propofol decreases in vivo binding of 11C-PBR28 to translocator protein (18 kDa) in the human brain. J Nucl Med. 2013; 54: 64-9
|
|
|
|
|
|
19）Kalk NJ, Owen DR, Tyacke RJ, et al. Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies? Synapse. 2013; 67: 909-12
|
|
|
|
|
|
20）Kreisl WC, Fujita M, Fujimura Y, et al. Comparison of [(11)C]-(R)-PK 11195 and [(11)C]PBR28, two radioligands for translocator protein (18 kDa) in human and monkey: Implications for positron emission tomographic imaging of this inflammation biomarker. Neuroimage. 2010; 49: 2924-32
|
|
|
|
|
|
21）Owen DR, Gunn RN, Rabiner EA, et al. Mixed-affinity binding in humans with 18-kDa translocator protein ligands. J Nucl Med. 2011; 52: 24-32
|
|
|
|
|
|
22）Owen DR, Howell OW, Tang SP, et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab. 2010; 30: 1608-18
|
|
|
|
|
|
23）Owen DR, Lewis AJ, Reynolds R, et al. Variation in binding affinity of the novel anxiolytic XBD173 for the 18 kDa translocator protein in human brain. Synapse. 2011; 65: 257-9
|
|
|
|
|
|
24）Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimerʼs disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010; 9: 363-72
|
|
|
|
|
|
25）Okamura N, Furumoto S, Harada R, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 2013; 54: 1420-7
|
|
|
|
|
|
26）Chien DT, Szardenings AK, Bahri S, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. J Alzheimers Dis. 2013; 38: 171-84
|
|
|
|
|
|
27）Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 2013; 79: 1094-108
|
|
|
|
|